Imunon’s (IMNN) Buy Rating Reaffirmed at D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $29.00 target price on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Imunon in a research note on Thursday, December 19th.

Imunon Price Performance

Shares of Imunon stock traded up $0.01 on Monday, reaching $0.96. 38,152 shares of the company were exchanged, compared to its average volume of 899,218. Imunon has a 1-year low of $0.64 and a 1-year high of $3.65. The stock’s 50 day moving average price is $0.89 and its 200-day moving average price is $0.91. The company has a market cap of $13.96 million, a P/E ratio of -0.51 and a beta of 1.96.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC lifted its position in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned approximately 0.96% of Imunon worth $133,000 at the end of the most recent quarter. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.